Zhao X.-H.,Provincial Hospital of Hebei |
Jia Y.-T.,Provincial Hospital of Hebei |
Wang Z.-M.,First Peoples Hospital of Xingtai |
Geng W.,Provincial Hospital of Hebei |
Liu B.,Provincial Hospital of Hebei
Chinese Journal of Cancer Biotherapy | Year: 2010
Objective: To observe the short-term efficacy and toxicity of Endostar combined with image guided radiation therapy (IGRT) in treatment of non-small-cell lung cancer (NSCLC) patients with brain metastasis. Methods: Forty NSCLC patients with brain metastasis, who were treated in the Department of Oncology of Provincial Hospital of Hebei during Jan. 2008 to Jun. 2008, were enrolled in the present study, and were randomly divided into trial group (22 cases) and control group (18 cases). The trial group received Endostar combined with IGRT (Endostar + IGRT group) and the control group received only IGRT at the same dosage (IGRT group). The short-term efficacy was evaluated by RESICT criteria and toxicity was evaluated according to NCI CTC Version 3.0 criteria. Results: The overall response rate was 77.3% in Endostar + IGRT group versus 61.1% in IGRT group (P < 0.05). The clinical benefit rates in the Endostar + IGRT group and IGRT group were 90.9% and 72.2%, respectively (P < 0.05). The main toxicities were leucopenia, nausea/vomiting and acratia, and their incidences in Endostar + IGRT group were similar to those in IGRT group (P > 0.05). The median free time to progression was 11.6 months in the Endostar + IGRT group and 11.3 months in the IGRT group (P > 0.05); the one year survival rates were 54.5% and 55.6%, respectively, with no difference between the two groups (P > 0.05). Conclusion: Endostar combined with IGRT can increase the total effective rate and clinical benefit of NSCLC patients with brain metastasis.